Clinical Trial Update: Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating nivolumab plus ipilimumab in prostate cancer with an immunogenic signature.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: University College, London | Conditions: Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING